In 2022, the efficacy of anti-LAG-3 combined with anti-PD-1 was first evaluated in patients with advanced melanoma, demonstrating a nearly 48% 12-month PFS compared to 36% in those treated with anti-PD-1 alone [53]. The gene discussed is PDCD1; the disease is melanoma.